Literature DB >> 17154546

Proteolytic fragments of insulysin (IDE) retain substrate binding but lose allosteric regulation.

Eun Suk Song1, Clint Cady, Michael G Fried, Louis B Hersh.   

Abstract

Treatment of an N-terminal-containing His6-tagged insulysin (His6-IDE) with proteinase K led to the initial cleavage of the His tag and linker region. This was followed by C-terminal cleavages resulting in intermediate fragments of approximately 95 and approximately 76 kDa and finally a relatively stable approximately 56 kDa fragment. The approximately 76 and approximately 56 kDa fragments exhibited a low level of catalytic activity but retained the ability to bind the substrate with a similar affinity as the native enzyme. The kinetics of the reaction of the IDE approximately 76 and approximately 56 kDa proteolytic fragments with a synthetic fluorogenic substrate produced hyperbolic substrate versus velocity curves, rather than the sigmoidal curve obtained with His6-IDE. The approximately 76 and approximately 56 kDa IDE proteolytic fragments were active toward the physiological peptides beta-endorphin, insulin, and amyloid beta peptide 1-40. Although activity was reduced by a factor of approximately 103-104 with these substrates, the relative activity and the cleavage sites were unchanged. Both the approximately 76 and approximately 56 kDa fragments retained the regulatory cationic binding site that binds ATP. Thus, the two proteinase K cleavage fragments of IDE retain the substrate- and ATP-binding sites but have low catalytic activity and lose the allosteric kinetic behavior of IDE. These data suggest a role of the C-terminal region of IDE in allosteric regulation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17154546      PMCID: PMC2519894          DOI: 10.1021/bi061298u

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  27 in total

1.  Degradation of amyloid beta-protein by a metalloprotease secreted by microglia and other neural and non-neural cells.

Authors:  W Q Qiu; Z Ye; D Kholodenko; P Seubert; D J Selkoe
Journal:  J Biol Chem       Date:  1997-03-07       Impact factor: 5.157

2.  New fluorogenic substrates for N-arginine dibasic convertase.

Authors:  E Csuhai; M A Juliano; J S Pyrek; A C Harms; L Juliano; L B Hersh
Journal:  Anal Biochem       Date:  1999-04-10       Impact factor: 3.365

3.  The C-terminal domain of human insulin degrading enzyme is required for dimerization and substrate recognition.

Authors:  Pengyun Li; Wen-Liang Kuo; Mohammed Yousef; Marsha Rich Rosner; Wei-Jen Tang
Journal:  Biochem Biophys Res Commun       Date:  2006-03-22       Impact factor: 3.575

4.  Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme.

Authors:  J R McDermott; A M Gibson
Journal:  Neurochem Res       Date:  1997-01       Impact factor: 3.996

5.  ATP effects on insulin-degrading enzyme are mediated primarily through its triphosphate moiety.

Authors:  Eun Suk Song; Maria Aparecida Juliano; Luiz Juliano; Michael G Fried; Steven L Wagner; Louis B Hersh
Journal:  J Biol Chem       Date:  2004-10-19       Impact factor: 5.157

6.  Mutation of active site residues of insulin-degrading enzyme alters allosteric interactions.

Authors:  Eun Suk Song; Abigail Daily; Michael G Fried; Maria Aparecida Juliano; Luiz Juliano; Louis B Hersh
Journal:  J Biol Chem       Date:  2005-03-03       Impact factor: 5.157

7.  Characterization of the nucleotide binding properties of SV40 T antigen using fluorescent 3'(2')-O-(2,4,6-trinitrophenyl)adenine nucleotide analogues.

Authors:  S G Huang; K Weisshart; E Fanning
Journal:  Biochemistry       Date:  1998-11-03       Impact factor: 3.162

8.  Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme.

Authors:  I V Kurochkin; S Goto
Journal:  FEBS Lett       Date:  1994-05-23       Impact factor: 4.124

9.  Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation.

Authors:  W Q Qiu; D M Walsh; Z Ye; K Vekrellis; J Zhang; M B Podlisny; M R Rosner; A Safavi; L B Hersh; D J Selkoe
Journal:  J Biol Chem       Date:  1998-12-04       Impact factor: 5.157

10.  Substrate activation of insulin-degrading enzyme (insulysin). A potential target for drug development.

Authors:  Eun-Suk Song; Maria Aparecida Juliano; Luiz Juliano; Louis B Hersh
Journal:  J Biol Chem       Date:  2003-10-02       Impact factor: 5.157

View more
  4 in total

1.  Dual Exosite-binding Inhibitors of Insulin-degrading Enzyme Challenge Its Role as the Primary Mediator of Insulin Clearance in Vivo.

Authors:  Timothy B Durham; James L Toth; Valentine J Klimkowski; Julia X C Cao; Angela M Siesky; Jesline Alexander-Chacko; Ginger Y Wu; Jeffrey T Dixon; James E McGee; Yong Wang; Sherry Y Guo; Rachel Nicole Cavitt; John Schindler; Stefan J Thibodeaux; Nathan A Calvert; Michael J Coghlan; Dana K Sindelar; Michael Christe; Vladislav V Kiselyov; M Dodson Michael; Kyle W Sloop
Journal:  J Biol Chem       Date:  2015-06-17       Impact factor: 5.157

2.  In vitro degradation of insulin-like peptide 3 by insulin-degrading enzyme.

Authors:  Wei-Jie Zhang; Xiao Luo; Zhan-Yun Guo
Journal:  Protein J       Date:  2010-02       Impact factor: 2.371

3.  The amino terminus of varicella-zoster virus (VZV) glycoprotein E is required for binding to insulin-degrading enzyme, a VZV receptor.

Authors:  Qingxue Li; Tammy Krogmann; Mir A Ali; Wei-Jen Tang; Jeffrey I Cohen
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103

4.  Identification of the allosteric regulatory site of insulysin.

Authors:  Nicholas Noinaj; Sonia K Bhasin; Eun Suk Song; Kirsten E Scoggin; Maria A Juliano; Luiz Juliano; Louis B Hersh; David W Rodgers
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.